Presentation is loading. Please wait.

Presentation is loading. Please wait.

Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms  Raffaela.

Published byLuiz Felipe Bayer Modified over 5 years ago

Similar presentations

Presentation on theme: "Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms  Raffaela."— Presentation transcript:

1 Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms  Raffaela Campana, PhD, Katharina Marth, MD, Petra Zieglmayer, MD, Milena Weber, MSc, Christian Lupinek, MD, Yury Zhernov, MD, PhD, Olga Elisyutina, MD, Musa Khaitov, MD, PhD, Eva Rigler, MD, PhD, Kerstin Westritschnig, MD, Uwe Berger, MBA, Martin Wolkersdorfer, PhD, Fritz Horak, MD, Friedrich Horak, MD, Rudolf Valenta, MD  Journal of Allergy and Clinical Immunology  Volume 143, Issue 3, Pages (March 2019) DOI: /j.jaci Copyright © 2018 The Authors Terms and Conditions

2 Fig 1 Scheme, time course of study, and development of specific IgG responses. A, The study was conducted over a period of 2 years (x-axis: weeks). The 13 study visits are indicated as well as the time points of vaccination (I-IV), blood sampling, and skin testing. Development of specific IgG responses (y-axes: OD increases compared with baseline) against, Bet v 1 (B), F1 (C), F2 (D) birch pollen–specific IgE (E) (y-axis: kUA/L), and birch pollen–induced wheal reactions (F) (y-axis: mm2) during the 2 years of the study (x-axes: wk/visits) in the active group (grey) and the placebo group (black). Time points of vaccination and pollen seasons (boxed) are indicated. SPT, Skin prick test. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

3 Fig 2 Inhibition of IgE binding to Bet v 1 by treatment-induced antibodies in patients with allergy. Shown are the percentages of inhibition as box plots with median and lower and upper quartiles of IgE binding of patients (BPA 1-11) obtained by preincubation of ELISA plate-bound Bet v 1 with sera from actively treated (black) or placebo-treated subjects (grey) taken at the different visits indicated (x-axes) (Table E5). BPA, Birch pollen allergic patient. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2018 The Authors Terms and Conditions

Download ppt "Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms  Raffaela."

Similar presentations

Volume 11, Pages (September 2016)

Volume 11, Pages (September 2016)
Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.

Repeated low-dose intradermal allergen injection suppresses allergen-induced cutaneous late responses  Giuseppina Rotiroti, MD, Mohamed Shamji, PhD, Stephen.
Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study  Anna.

Sensitization to cat and dog allergen molecules in childhood and prediction of symptoms of cat and dog allergy in adolescence: A BAMSE/MeDALL study  Anna.
Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy  Christian Lupinek, Kurt Derfler, Silvia Lee, Thomas Prikoszovich, Oliver Movadat,

Extracorporeal IgE Immunoadsorption in Allergic Asthma: Safety and Efficacy  Christian Lupinek, Kurt Derfler, Silvia Lee, Thomas Prikoszovich, Oliver Movadat,
Volume 11, Pages (September 2016)

Volume 11, Pages (September 2016)
Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines 

Comparison of the immunogenicity of BM32, a recombinant hypoallergenic B cell epitope–based grass pollen allergy vaccine with allergen extract–based vaccines 
Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies  Marija Geroldinger-Simic, MD, Thomas Zelniker,

Birch pollen–related food allergy: Clinical aspects and the role of allergen-specific IgE and IgG4 antibodies  Marija Geroldinger-Simic, MD, Thomas Zelniker,
Cor a 1–reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen–associated food allergy to hazelnut  Claudia.

Cor a 1–reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen–associated food allergy to hazelnut  Claudia.
Kuan-Wei Chen, PhD, Katharina Blatt, MSc, Wayne R

Kuan-Wei Chen, PhD, Katharina Blatt, MSc, Wayne R
Identification of common allergenic structures in mugwort and ragweed pollen  Reinhold Hirschwehr, MDa, Claudia Heppner, MSca, Susanne Spitzauer, MDb,

Identification of common allergenic structures in mugwort and ragweed pollen  Reinhold Hirschwehr, MDa, Claudia Heppner, MSca, Susanne Spitzauer, MDb,
Identification of allergens in fruits and vegetables: IgE cross-reactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin) 

Identification of allergens in fruits and vegetables: IgE cross-reactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin) 
Frequent occurrence of T cell–mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments  Raffaela Campana, PhD, Katharina.

Frequent occurrence of T cell–mediated late reactions revealed by atopy patch testing with hypoallergenic rBet v 1 fragments  Raffaela Campana, PhD, Katharina.
Giant ragweed specific immunotherapy is not effective in a proportion of patients sensitized to short ragweed: Analysis of the allergenic differences.

Giant ragweed specific immunotherapy is not effective in a proportion of patients sensitized to short ragweed: Analysis of the allergenic differences.
Cor a 1–reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen–associated food allergy to hazelnut  Claudia.

Cor a 1–reactive T cells and IgE are predominantly cross-reactive to Bet v 1 in patients with birch pollen–associated food allergy to hazelnut  Claudia.
Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy  Margarete Focke-Tejkl, PhD, Milena.

Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy  Margarete Focke-Tejkl, PhD, Milena.
Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy  Raphaela.

Blocking antibodies induced by immunization with a hypoallergenic parvalbumin mutant reduce allergic symptoms in a mouse model of fish allergy  Raphaela.
Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule  Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,

Skin test diagnosis of grass pollen allergy with a recombinant hybrid molecule  Carine Metz-Favre, MD, Birgit Linhart, PhD, Margarete Focke-Tejkl, PhD,
Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32  Verena Niederberger, MD, Angela Neubauer, PhD,

Safety and efficacy of immunotherapy with the recombinant B-cell epitope–based grass pollen vaccine BM32  Verena Niederberger, MD, Angela Neubauer, PhD,
Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies 

Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies 
Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis  Friedrich Horak, MD, Kamal D.

Randomized phase 1 study of the phosphatidylinositol 3-kinase δ inhibitor idelalisib in patients with allergic rhinitis  Friedrich Horak, MD, Kamal D.

Similar presentations

Ads by Google